CA2330190A1 - Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells - Google Patents
Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells Download PDFInfo
- Publication number
- CA2330190A1 CA2330190A1 CA002330190A CA2330190A CA2330190A1 CA 2330190 A1 CA2330190 A1 CA 2330190A1 CA 002330190 A CA002330190 A CA 002330190A CA 2330190 A CA2330190 A CA 2330190A CA 2330190 A1 CA2330190 A1 CA 2330190A1
- Authority
- CA
- Canada
- Prior art keywords
- stem cells
- cells
- hematopoietic
- osteoclasts
- hematopoietic stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0643—Osteoclasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/10—Mineral substrates
- C12N2533/18—Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
Abstract
The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.
Claims (15)
1. A method for producing osteoclasts in vitro comprising co-culturing mesenchymal stem cells with hematopoietic stem cells such that the hematopoietic stem cells produce osteoclasts.
2. The method of claim 2 wherein co-culturing is done in the absence of exogenous cytokines.
3. The method of claim 1 wherein the hematopoietic stem cells are CD34+
cells.
cells.
4. The method of claim 1 wherein the hematopoietic stem cells and the mesenchymal stem cells are in contact.
5. A method of producing genetically modified osteoclasts, comprising transducing hematopoietic progenitor cells with exogenous genetic material;
and culturing the transduced hematopoietic cells in the presence of mesenchymal stem cells to induce differentiation of the transduced hematopoietic cells into osteoclasts which contain the exogenous genetic material.
and culturing the transduced hematopoietic cells in the presence of mesenchymal stem cells to induce differentiation of the transduced hematopoietic cells into osteoclasts which contain the exogenous genetic material.
6. The method of claim 5 wherein the transduced hematopoietic stem cells are induced to differentiate in vitro.
7. The method of claim 5 wherein the transduced hematopoietic stem cells are induced to differentiate in vivo.
8. A method of obtaining genetically modified osteoclasts comprising transducing hematopoietic progenitor cells with exogenous genetic material and placing the transduced hematopoietic cells under conditions suitable for differentiation of the hematopoietic stem cells into osteoclast cells which contain the exogenous genetic material.
9. The method of claim 8 wherein the hematopoietic cells are differentiated in vivo.
10. The method of claim 8 wherein the hematopoietic cells are administered in vivo with human mesenchymal stem cells.
11. A composition comprising genetically modified osteoclasts.
12. The composition of claim 11 wherein the genetically modified osteoclasts are from a non-transformed cell line.
13. A composition comprising genetically modified osteoclast precursor cells.
14. The composition of claim 13 wherein the genetically modified osteoclast precursor cells are from a non-transformed cell line.
15. A method for decreasing differentiation of hematopoietic stem cells into osteoclasts comprising co-culturing differentiating mesenchymal stem cells with hematopoietic stem cells such that osteoclastogenesis is reduced.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002680649A CA2680649A1 (en) | 1998-06-08 | 1999-06-08 | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8843198P | 1998-06-08 | 1998-06-08 | |
US60/088,431 | 1998-06-08 | ||
US9923398P | 1998-09-04 | 1998-09-04 | |
US60/099,233 | 1998-09-04 | ||
PCT/US1999/012847 WO1999064565A2 (en) | 1998-06-08 | 1999-06-08 | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002680649A Division CA2680649A1 (en) | 1998-06-08 | 1999-06-08 | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2330190A1 true CA2330190A1 (en) | 1999-12-16 |
CA2330190C CA2330190C (en) | 2009-12-22 |
Family
ID=26778653
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002330190A Expired - Fee Related CA2330190C (en) | 1998-06-08 | 1999-06-08 | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
CA002680649A Abandoned CA2680649A1 (en) | 1998-06-08 | 1999-06-08 | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002680649A Abandoned CA2680649A1 (en) | 1998-06-08 | 1999-06-08 | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
Country Status (12)
Country | Link |
---|---|
US (1) | US6255112B1 (en) |
EP (1) | EP1084230B1 (en) |
JP (1) | JP2003505006A (en) |
AT (1) | ATE375799T1 (en) |
AU (1) | AU4336499A (en) |
CA (2) | CA2330190C (en) |
CY (1) | CY1107121T1 (en) |
DE (1) | DE69937347T2 (en) |
DK (1) | DK1084230T3 (en) |
ES (1) | ES2296413T3 (en) |
PT (1) | PT1084230E (en) |
WO (1) | WO1999064565A2 (en) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1218487A2 (en) * | 1999-09-23 | 2002-07-03 | Cell Science Therapeutics | Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells |
WO2002040639A2 (en) * | 2000-11-14 | 2002-05-23 | The University Of Louisville Research Foundation, Inc. | Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
KR100915482B1 (en) | 2000-12-06 | 2009-09-03 | 하리리 로버트 제이 | Method of collecting placental stem cells |
EP1362095B1 (en) | 2001-02-14 | 2015-05-27 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
NZ528035A (en) * | 2001-02-14 | 2005-07-29 | Robert J Hariri | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
US20030082184A1 (en) * | 2001-08-08 | 2003-05-01 | Bazan J. Fernando | Uses of mammalian cytokine; related reagents |
CA2477411A1 (en) * | 2002-03-02 | 2003-09-12 | Board Of Regents, The University Of Texas | Local production and/or delivery of anti-cancer agents by stromal cell precursors |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
EP1525308A4 (en) * | 2002-05-30 | 2006-11-02 | Celgene Corp | Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
EP1571910A4 (en) | 2002-11-26 | 2009-10-28 | Anthrogenesis Corp | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
ATE482725T1 (en) * | 2003-04-01 | 2010-10-15 | Us Dept Of Veteran S Affaires | STEM CELL, PROGRESSOR CELL OR TARGET CELL BASED TREATMENT OF MULTI-ORGAN FAILURE. |
US20040209246A1 (en) * | 2003-04-15 | 2004-10-21 | Agouron Pharmaceuticals, Inc. | Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors |
EP1479760A1 (en) * | 2003-05-19 | 2004-11-24 | ProBioGen AG | Artificial immune organ |
EP2450433A3 (en) | 2003-10-08 | 2012-08-08 | Vet-Stem Inc | Methods of preparing and using stem cell compositions and kits comprising the same |
US20050112551A1 (en) * | 2003-11-24 | 2005-05-26 | Agouron Pharmaceuticals, Inc. | Dual assay for evaluating activity and cytotoxicity of compounds in the same population of cells |
EP1799812A4 (en) | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
CA2512667A1 (en) * | 2005-01-07 | 2006-07-07 | Takahiro Ochiya | Human hepatocyte-like cells and uses thereof |
CA2608048A1 (en) * | 2005-05-10 | 2006-11-16 | United States Of America Department Of Veteran's Affairs | Therapy of kidney diseases and multiorgan failure with mesenchymal stem cells and mesenchymal stem cell conditioned media |
ES2452595T3 (en) | 2005-10-13 | 2014-04-02 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
US8846393B2 (en) * | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
PL2471904T3 (en) | 2005-12-29 | 2019-08-30 | Celularity, Inc. | Placental stem cell populations |
US8455250B2 (en) | 2005-12-29 | 2013-06-04 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
ZA200810412B (en) * | 2006-06-09 | 2010-03-31 | Anthrogenesis Corp | Placental niche and use thereof to culture stem cells |
US7993918B2 (en) * | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
KR100818213B1 (en) | 2006-09-22 | 2008-04-01 | 재단법인서울대학교산학협력재단 | Human Cord Blood Multipotent Stem Cell Having Enhanced Proliferation Ability With Osteoclast-based Niche-like Structure and Method for Preparing the Same |
US20080118477A1 (en) * | 2006-11-09 | 2008-05-22 | Rush University Medical Center | Umbilical cord mesenchymal stem cells support cord blood hematopoiesis |
EP2129775A1 (en) | 2007-02-12 | 2009-12-09 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations |
AU2008216749B2 (en) | 2007-02-12 | 2014-03-13 | Celularity Inc. | Treatment of inflammatory diseases using placental stem cells |
US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
CN101173247B (en) * | 2007-08-08 | 2010-06-02 | 中国人民解放军军事医学科学院基础医学研究所 | Method for culturing osteoclast with mesenchyma stem cell combined with cell factor |
EP2783692B1 (en) | 2007-09-28 | 2019-01-02 | Celularity, Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
CN105796602A (en) | 2008-08-20 | 2016-07-27 | 人类起源公司 | Treatment of stroke using isolated placental cells |
MX2011001990A (en) | 2008-08-20 | 2011-03-29 | Anthrogenesis Corp | Improved cell composition and methods of making the same. |
CN102176919A (en) | 2008-08-22 | 2011-09-07 | 人类起源公司 | Methods and compositions for treatment of bone defects with placental cell populations |
KR20110086176A (en) | 2008-11-19 | 2011-07-27 | 안트로제네시스 코포레이션 | Amnion derived adherent cells |
CA2767014C (en) | 2009-07-02 | 2022-01-25 | Anthrogenesis Corporation | Method of producing erythrocytes without feeder cells |
US20120177618A1 (en) * | 2009-07-14 | 2012-07-12 | Massachusetts Institute Of Technology | Hematopoietic stromal progenitor cells and uses thereof |
JP5827220B2 (en) | 2010-01-22 | 2015-12-02 | 国立大学法人京都大学 | Method for improving the efficiency of establishment of induced pluripotent stem cells |
ES2646750T3 (en) | 2010-01-26 | 2017-12-15 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
SI2556145T1 (en) | 2010-04-07 | 2017-01-31 | Anthrogenesis Corporation | Angiogenesis using placental stem cells |
KR20130092394A (en) | 2010-04-08 | 2013-08-20 | 안트로제네시스 코포레이션 | Treatment of sarcoidosis using placental stem cells |
NZ605505A (en) | 2010-07-13 | 2015-02-27 | Anthrogenesis Corp | Methods of generating natural killer cells |
EP2625264B1 (en) | 2010-10-08 | 2022-12-07 | Terumo BCT, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
US9506039B2 (en) | 2010-12-03 | 2016-11-29 | Kyoto University | Efficient method for establishing induced pluripotent stem cells |
AR093183A1 (en) | 2010-12-31 | 2015-05-27 | Anthrogenesis Corp | INCREASE IN THE POWER OF PLACENTA MOTHER CELLS USING MODULATING RNA MOLECULES |
EP3443968A1 (en) | 2011-06-01 | 2019-02-20 | Celularity, Inc. | Treatment of pain using placental stem cells |
US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
CA2863795A1 (en) | 2012-02-13 | 2013-08-22 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
US9765296B2 (en) | 2013-09-04 | 2017-09-19 | Otsuka Pharmaceutical Factory, Inc. | Method for preparing pluripotent stem cells |
WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
KR101566450B1 (en) * | 2015-04-03 | 2015-11-05 | (유)스템메디케어 | A Method for mass production of proteins from mesenchymal stem cells |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
DE4322570C1 (en) * | 1993-07-07 | 1994-06-16 | Gsf Forschungszentrum Umwelt | Stromal cell lines from human bone marrow cells - contain SV-40 DNA with defective origin of replication, useful as feeder cells, for prodn. of growth factors and for gene expression |
US5719058A (en) * | 1995-04-10 | 1998-02-17 | Merck & Co., Inc. | Method for producing a highly enriched population of osteoclast cells |
-
1999
- 1999-06-08 US US09/327,796 patent/US6255112B1/en not_active Expired - Lifetime
- 1999-06-08 AT AT99955496T patent/ATE375799T1/en not_active IP Right Cessation
- 1999-06-08 JP JP2000553555A patent/JP2003505006A/en active Pending
- 1999-06-08 AU AU43364/99A patent/AU4336499A/en not_active Abandoned
- 1999-06-08 EP EP99955496A patent/EP1084230B1/en not_active Expired - Lifetime
- 1999-06-08 ES ES99955496T patent/ES2296413T3/en not_active Expired - Lifetime
- 1999-06-08 CA CA002330190A patent/CA2330190C/en not_active Expired - Fee Related
- 1999-06-08 PT PT99955496T patent/PT1084230E/en unknown
- 1999-06-08 WO PCT/US1999/012847 patent/WO1999064565A2/en active IP Right Grant
- 1999-06-08 CA CA002680649A patent/CA2680649A1/en not_active Abandoned
- 1999-06-08 DE DE69937347T patent/DE69937347T2/en not_active Expired - Lifetime
- 1999-06-08 DK DK99955496T patent/DK1084230T3/en active
-
2008
- 2008-01-02 CY CY20081100007T patent/CY1107121T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1999064565A3 (en) | 2000-02-24 |
CA2330190C (en) | 2009-12-22 |
ATE375799T1 (en) | 2007-11-15 |
EP1084230B1 (en) | 2007-10-17 |
ES2296413T3 (en) | 2008-04-16 |
DE69937347T2 (en) | 2008-09-04 |
EP1084230A2 (en) | 2001-03-21 |
CY1107121T1 (en) | 2012-10-24 |
JP2003505006A (en) | 2003-02-12 |
WO1999064565A9 (en) | 2000-04-13 |
DE69937347D1 (en) | 2007-11-29 |
PT1084230E (en) | 2008-01-25 |
DK1084230T3 (en) | 2008-03-03 |
AU4336499A (en) | 1999-12-30 |
US6255112B1 (en) | 2001-07-03 |
WO1999064565A2 (en) | 1999-12-16 |
CA2680649A1 (en) | 1999-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2330190A1 (en) | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells | |
JP2003505006A5 (en) | ||
Quirici et al. | Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies | |
Sessarego et al. | Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application | |
Yildirim et al. | The comparison of the immunologic properties of stem cells isolated from human exfoliated deciduous teeth, dental pulp, and dental follicles | |
US6030836A (en) | Vitro maintenance of hematopoietic stem cells | |
EP1100878B8 (en) | Process for producing genetically modified cd34-negative adherently growing haematopoietic stem cells | |
Tuli et al. | A simple, high-yield method for obtaining multipotential mesenchymal progenitor cells from trabecular bone | |
Krampera et al. | Regenerative and immunomodulatory potential of mesenchymal stem cells | |
Dexter et al. | Stromal cells in haemopoiesis | |
Nasef et al. | Selected Stro‐1‐enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation | |
US8574567B2 (en) | Multipotent stem cells and uses thereof | |
KR20050044395A (en) | Methods and compositions for the use of stromal cells to support embryonic and adult stem cells | |
Antonucci et al. | Isolation of osteogenic progenitors from human amniotic fluid using a single step culture protocol | |
Yustianingsih et al. | Hypoxia enhances self-renewal properties and markers of mesenchymal stem cells | |
KR20050042215A (en) | Endothelial cells derived from primate embryonic stem cells | |
Rosenzweig et al. | Enhanced maintenance and retroviral transduction of primitive hematopoietic progenitor cells using a novel three-dimensional culture system | |
Lupo et al. | Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum-and feeder-free conditions | |
Müller et al. | In vitro analysis of multipotent mesenchymal stromal cells as potential cellular therapeutics in neurometabolic diseases in pediatric patients | |
Morsczeck et al. | Stem and progenitor cells of dental and gingival tissue origin | |
Nakamura et al. | Culture medium study of human mesenchymal stem cells for practical use of tissue engineering and regenerative medicine | |
Min et al. | Long-term bone marrow culture-derived stromal fibroblasts as a potential target for gene therapy in acute myelogenous leukemia | |
Krylova et al. | Cellular spheroids obtained from mesenchymal stem cells derived from bone marrow and limb muscle of early human embryo | |
Bryja et al. | Overview of the different methods used in the primary culture of oral mucosa cells | |
Takagi et al. | Spatial development of the cultivation of a bone marrow stromal cell line in porous carriers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |